Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties
Chanil Moon(National Institute on Aging), Mark I. Talan(National Institute on Aging), Steven J. Sollott(National Institute on Aging), Edward G. Lakatta(Johns Hopkins University), Thomas R. Coleman(University of Messina), Doo‐Jin Paik(National Institute on Aging), Melissa Krawczyk(National Institute on Aging), Magdalena Juhaszova(Institute on Aging), Michael Brines(Northwell Health)
Cited by 96
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Elevated Aortic Pulse Wave Velocity, a Marker of Arterial Stiffness, Predicts Cardiovascular Events in Well-Functioning Older Adults
|Circulation|2005|1.2k
Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises
|Circulation|2003|1.1k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k